Medical device manufacturer Medtronic today revealed results from a three-month post-market clinical study of spinal cord stimulation through its EvolveSM workflow, endorsing effective pain relief and improved function in patients with chronic intractable back and leg pain.
Results of the study were presented at the American Society of Interventional Pain Physicians annual meeting.
Three key insights:
1. The Evolve workflow aims to help physicians balance high- and low-dose therapy settings on Medtronic SCS systems. The study included 98 patients who underwent spinal cord stimulation with EvolveSM and completed a three-month follow-up visit.
2. Study authors found that 69 percent of patients had at least a 50 percent improvement in overall pain and 70 percent achieved a personal activity goal at three months. Altogether, 81 percent were satisfied with the therapy and 65 percent improved at least one disability category in the Oswestry Disability Index.
3. Results from the study indicated sustained pain relief, improved quality of life and decreased disability after device implant.
"More clinicians are seeking long-term, non-opioid treatments for chronic pain, so it's important to understand how to best optimize SCS treatment with tools like the Evolve workflow," said John Hatheway, MD, of Northwest Pain Care of Spokane (Wash.) and a primary investigator in the clinical trial. "The potential for SCS to provide meaningful long-term improvements in quality of life, activities of daily living, and function is critical."
More articles on devices:
Orthofix Q1 net income plummets 82.7%, spine implant sales up 10.6%: 5 details
Medtronic cuts senior position amid restructuring
Texas hospital fundraises for Mobile C-Arm device for minimally invasive surgery